MF59

MF59 is an adjuvant used in several vaccines, but is perhaps most well-known for its use in the Fluad influenza vaccine. It was developed by Novartis, a Swiss multinational pharmaceutical company, and is now owned by Seqirus, a subsidiary of CSL Limited.

Composition

MF59 is an oil-in-water emulsion composed of squalene (oil) in water, stabilized with the surfactants polysorbate 80 and sorbitan trioleate. The squalene is sourced from shark liver oil.

Mechanism of Action

The exact mechanism of action of MF59 is not fully understood. However, it is believed to work by enhancing the body's immune response to a vaccine. It does this by increasing the recruitment of immune cells to the injection site and enhancing the presentation of the antigen to the immune system.

Safety and Efficacy

MF59 has been used in vaccines for over 20 years and has a well-established safety profile. It has been used in more than 30 countries, including the United States, Canada, and countries in the European Union. The safety and efficacy of MF59-adjuvanted vaccines have been demonstrated in numerous clinical trials involving tens of thousands of participants, including children, adults, and the elderly.

Use in Vaccines

MF59 is used in several vaccines, including the Fluad influenza vaccine and the Foclivia vaccine for shingles. It is also being investigated for use in vaccines for diseases such as HIV, malaria, and tuberculosis.

Controversies

Despite its well-established safety profile, MF59 has been the subject of some controversy. Some people have raised concerns about the use of squalene, a naturally occurring substance in the body, as an adjuvant. However, these concerns are largely based on misinformation and misunderstanding. The amount of squalene used in vaccines is much less than the amount naturally present in the body.

See Also

• Adjuvant
• Vaccine
• Fluad
• Foclivia
• Novartis
• Seqirus
• CSL Limited

References

This article is a stub related to pharmacology. You can help WikiMD by expanding it!